Eculizumab
โ ๏ธ Most serious risk: life-threatening Neisserial infections (โ0.5%/year; 5% after 10 years).
โ
All patients treated with eculizumab must be vaccinated against Neisseria meningitidis.
๐ About
- Always check the BNF entry here for up-to-date prescribing advice.
- Prescribing and monitoring are specialist-only.
โ๏ธ Mode of Action
- Humanised monoclonal antibody that binds to complement protein C5.
- Blocks terminal complement activation โ prevents formation of the membrane attack complex (MAC).
- Compensates for CD59 deficiency in Paroxysmal Nocturnal Haemoglobinuria (PNH).
- Reduces intravascular haemolysis in PNH and complement-mediated microangiopathy in aHUS.
๐ฏ Indications & Dosing (Specialist Use)
| Condition | Initial Dose | Maintenance |
| PNH |
600 mg IV weekly ร 4 โ 900 mg IV week 5 |
900 mg IV every 12โ16 days |
| aHUS |
900 mg IV weekly ร 4 โ 1.2 g IV week 5 |
1.2 g IV every 12โ16 days |
๐ Interactions
โ ๏ธ Cautions
- Increased risk of severe infections, esp. meningococcal.
- Ensure vaccination before treatment and monitor closely.
๐ซ Contraindications
- Unvaccinated against Neisseria meningitidis.
- Ongoing meningococcal infection.
๐ฅ Side Effects
- Common: Headache (esp. after first few doses), diarrhoea, dizziness, chills.
- Occasional: Alopecia.โ ๏ธ Serious: Sepsis, meningococcal meningitis.
๐ References